1.3 C
Ankara
Pazartesi, Aralık 23, 2024

Markku Maki

Celimmune Commences First-Ever Dosing with AMG 714 in Celiac Disease

Celimmune LLC, a clinical development-stage immunotherapy company focused on treating and preventing immune-mediated diseases, announced that it has dosed the first patient in its Phase 2 clinical study for AMG 714 in celiac disease.
- Advertisement -spot_img

Latest News

Elveda…

Yaşam İçin Gıda Haber Sitesinin Kurucusu, Genel Yayın Yönetmeni Sayın Metin Ertunç 20 Mayıs 2021 tarihinde geçirdiği kalp krizi...
- Advertisement -spot_img